Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3023761 | 0.91 | TLR7 (0.50) | TLR7NUDT1NCF1APPTSHR | |
| Hydrochloric Acid SCHEMBL3231113 | 0.89 | TLR7 (0.49) | TLR7NUDT1NCF1APPTSHR | |
| SCHEMBL28036770 | 0.78 | DCPS (0.49) | NCF1APPTSHRDCPSNPC1 | |
| SCHEMBL30689003 | 0.78 | TLR8 (0.51) | NCF1APPDCPSNPC1PKM | |
| SCHEMBL2586754 | 0.76 | TLR8 (0.52) | TLR7NCF1DCPSNPC1PKM | |
| Hydrochloric Acid SCHEMBL6908984 | 0.76 | NCF1 (0.59) | NCF1TSHRDCPSNPC1PKM | |
| SCHEMBL27945207 | 0.75 | TSHR (0.55) | NCF1TSHRNPC1RAB9AKMT2A | |
| SCHEMBL14964747 | 0.74 | KMT2A (0.55) | NCF1APPDCPSNPC1PKM | |
| SCHEMBL8682782 | 0.74 | TSHR (0.46) | TLR7NUDT1NCF1TSHRKMT2A | |
| SCHEMBL28484277 | 0.73 | TSHR (0.43) | TLR7NUDT1NCF1TSHRMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101219999-A | N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101219999-A | N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101219999-A | N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-100351242-C | Processes and intermediates for preparing anti-cancer compounds | PFIZER PROD INC (US) | 2007-11-28 | — | — | CN | disclosed |
| CN-1699350-A | Processes and intermediates for preparing anti-cancer compounds | PFIZER PROD INC (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1215061-C | Process and intermediates for preparing anticancer compounds | PFIZER PROD INC (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1076652-B1 | N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE | OSI PHARM INC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040102463-A1 | N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| CN-1298396-A | N- (ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2001-06-06 | — | — | CN | disclosed |
| CN-1298396-A | N- (ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2001-06-06 | — | — | CN | disclosed |
| CN-1298396-A | N- (ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | OSI PHARM INC (US) | 2001-06-06 | — | — | CN | disclosed |
| EP-1076652-A1 | N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE | Pfizer Products Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| CN-1276370-A | Process and intermediates for preparing anticancer compounds | PFIZER PROD INC (US) | 2000-12-13 | — | — | CN | disclosed |
| WO-1999055683-A1 | N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE | PFIZER PRODUCTS INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102463-A1 | N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate | MKI67, KRAS, NNMT | TLR7 714/4885NUDT1 82/4885NCF1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.